SCHEMBL17782848

SCHEMBL17782848

C#Cc1cccc(-c2nc3cc(Nc4nc(-c5cccnc5)cs4)c(C)cc3[nH]2)c1

nearest known ligand 0.77

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
KIT P10721 20/20 0.77

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17782770 0.88 KIT (0.72) KIT
SCHEMBL17782818 0.87 KIT (1.00) KIT
SCHEMBL17782782 0.86 KIT (0.71) KIT
SCHEMBL17782832 0.86 KIT (0.80) KIT
SCHEMBL17782844 0.85 KIT (0.78) KIT
SCHEMBL17782856 0.85 KIT (0.85) KIT
SCHEMBL17782821 0.85 KIT (0.78) KIT
SCHEMBL21087110 0.85 KIT (0.77) KIT
SCHEMBL17782787 0.85 KIT (0.77) KIT
SCHEMBL17782861 0.84 KIT (1.00) KIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10202370-B2 Benzimidazole derivatives as selective proteine kinase inhibitors AB SCIENCE (FR) 2019-02-12 US claimed
US-20160152608-A1 BENZIMIDAZOLE DERIVATIVES AS SELECTIVE PROTEINE KINASE INHIBITORS AB SCIENCE (FR) 2016-06-02 US claimed
EP-3010906-B1 BENZIMIDAZOLE DERIVATIVES AS SELECTIVE PROTEIN KINASE INHIBITORS AB SCIENCE (FR) 2019-06-12 EP disclosed
US-10202370-B2 Benzimidazole derivatives as selective proteine kinase inhibitors AB SCIENCE (FR) 2019-02-12 US disclosed
US-20160152608-A1 BENZIMIDAZOLE DERIVATIVES AS SELECTIVE PROTEINE KINASE INHIBITORS AB SCIENCE (FR) 2016-06-02 US disclosed
US-20160152608-A1 BENZIMIDAZOLE DERIVATIVES AS SELECTIVE PROTEINE KINASE INHIBITORS AB SCIENCE (FR) 2016-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10202370-B2 Benzimidazole derivatives as selective proteine kinase inhibitors KIT, CHUK, CSNK1E KIT 1/4885
US-20160152608-A1 BENZIMIDAZOLE DERIVATIVES AS SELECTIVE PROTEINE KINASE INHIBITORS KIT, CHUK, CSNK1E KIT 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.